HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael F Egan Selected Research

verubecestat

12/2022Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer's disease.
1/2022A Model-Based Approach to Bridging Plasma and Dried Blood Spot Concentration Data for Phase 3 Verubecestat Trials.
1/2021Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy.
12/2020BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
11/2020Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
4/2019Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
1/2019Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
1/2019Verubecestat for Prodromal Alzheimer's Disease. Reply.
1/2018Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael F Egan Research Topics

Disease

26Schizophrenia (Dementia Praecox)
09/2013 - 05/2002
9Alzheimer Disease (Alzheimer's Disease)
12/2022 - 01/2018
6Psychotic Disorders (Schizoaffective Disorder)
03/2013 - 09/2003
2Dementia (Dementias)
04/2019 - 01/2018
2Mental Disorders (Mental Disorder)
04/2008 - 11/2004
2Genetic Predisposition to Disease (Genetic Predisposition)
12/2006 - 04/2003
2Mood Disorders (Mood Disorder)
02/2005 - 05/2002
1Atrophy
01/2021
1Disease Progression
04/2019
1Weight Loss (Weight Reduction)
01/2018
1Exanthema (Rash)
01/2018
1Wounds and Injuries (Trauma)
01/2018
1Parkinson Disease (Parkinson's Disease)
09/2013
1DiGeorge Syndrome (Syndrome, DiGeorge)
11/2008
122q11 Deletion Syndrome
11/2008
1Bipolar Disorder (Manic Depressive Psychosis)
09/2006
1Dyskinesias (Dyskinesia)
09/2003
1Tardive Dyskinesia
09/2003
1Leukopenia
10/2002

Drug/Important Bio-Agent (IBA)

9verubecestatIBA
12/2022 - 01/2018
7Antipsychotic Agents (Antipsychotics)IBA
09/2013 - 10/2002
4EnzymesIBA
01/2021 - 10/2002
4Dopamine (Intropin)FDA LinkGeneric
09/2013 - 09/2006
4Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA
01/2008 - 09/2003
3Pharmaceutical PreparationsIBA
04/2019 - 10/2002
2Amyloid (Amyloid Fibrils)IBA
12/2022 - 04/2019
2methionylmethionine (Met-Met)IBA
12/2006 - 11/2004
1Retinaldehyde (Retinal)IBA
01/2021
1lanabecestatIBA
11/2020
1Amyloid Precursor Protein Secretases (beta-Secretase)IBA
11/2020
1Amyloid beta-PeptidesIBA
01/2018
1T-Type Calcium Channels (T-Type Calcium Channel)IBA
03/2013
1Olanzapine (Zyprexa)FDA Link
03/2013
1Protein Isoforms (Isoforms)IBA
05/2009
1Proline Oxidase (Proline Dehydrogenase)IBA
11/2008
13' Untranslated Regions (3' UTR)IBA
04/2008
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
04/2008
1SolutionsIBA
08/2007
1N-Methylaspartate (NMDA)IBA
09/2006
1GTP-Binding Proteins (G-Protein)IBA
07/2006
1metabotropic glutamate receptor 3 (mGluR3)IBA
04/2006
1N-acetylaspartate (N-acetyl aspartate)IBA
04/2006
1Biomarkers (Surrogate Marker)IBA
03/2005
1Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
02/2005
1Brain-Derived Neurotrophic Factor (BDNF)IBA
11/2004
1valylvaline (Val-Val)IBA
11/2004
1Messenger RNA (mRNA)IBA
11/2004
1Proteins (Proteins, Gene)FDA Link
11/2004
1Glutamic Acid (Glutamate)FDA Link
08/2004
1Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA
08/2004
1Clozapine (Clozaril)FDA LinkGeneric
08/2003
1Biological ProductsIBA
04/2003
1Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA
01/2003
1Cholinergic Agents (Cholinergics)IBA
01/2003
1Acetylcholine (Acetylcholine Chloride)FDA Link
01/2003
1AMPA Receptors (AMPA Receptor)IBA
10/2002
11-(quinoxalin-6-ylcarbonyl)piperidine (CX516)IBA
10/2002
1propionic acid (potassium propionate)IBA
10/2002
1Neurotensin Receptors (Neurotensin Receptor)IBA
05/2002

Therapy/Procedure

2Therapeutics
09/2013 - 04/2008
1Activities of Daily Living (ADL)
01/2018
1Behavior Control
12/2006
1Aftercare (After-Treatment)
08/2003